Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of fianlimab + cemiplimab versus pembrolizumab in untreated advanced melanoma
2021-004453-23Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab, fianlimab and cemiplimab in cutaneous melanoma (CM) and melanoma (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Progression-free survival. Started Mar 2022; status: active.
02
Drugs
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2021-004453-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004453-23.